Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...
BenefitsPRO8d
Could GLP-1s cause pharmacy plan bottom lines to balloon in 2025?
With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...
Business Wire7d
Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults
While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature long ...
Benzinga.com7d
EXCLUSIVE: Vivani Medical Announces First Implant In Early-Stage Human Study Of GLP-1 Implant For Obesity
Vivani also expects the results to support the potential application of a GLP-1 (exenatide) implant for type 2 diabetes and other diseases. Find out which stock just plummeted to the bottom of the ...